Earnings Report: GlaxoSmithKline (PSX: GLAXO) today reported Financial Results for the Three and Six months ended June 30, 2017

GlaxoSmithKline announced Financial Results for the period ended June 30, 2017.

The company’s Sales for the period increased by 25 percent in the outgoing year, whereas the Total Profit after Taxation for the Period increased by 33 percent.

The board has recommended no Cash Dividend, any bonus or right shares.

Comparison of Key Financials

Unconsolidated Profit and Loss Account – For the Six Months Ended

Key Financials

Jan – June, 2017

Jan – Jun, 2016

% Change

 

Amounts in PKR ‘000

Sales

16,208,185

12,916,465

25%

Cost of Sales

11,824,067

9,510,709

24%

Gross Profit

4,384,118

3,405,756

29%

Selling, Marketing and Dist: Expenses

1,478,058

1,355,368

9%

Admin: Expenses

482,952

490,813

-2%

Other Operating Expenses

222,013

137,921

61%

Other Income

294,599

196,516

50%

Profit from Operations

2,495,694

1,618,170

54%

Finance Cost

9,761

8,598

14%

Profit before Taxation

2,485,933

1,609,752

54%

Taxation

1,027,937

675,049

52%

Profit after Taxation from Continued Operations

1,457,996

934,523

56%

(Loss)/Profit after Taxation from dis-continued Operations

(31,721)

138,816

-123%

Total Profit after Operations

1,426,275

1,073,339

33%

EPS – Continued Operations

4.58

2.93

56%

EPS – Discontinued Operations

(0.10)

0.44

-123%

EPS

4.48

3.37

33%

 

Company release on Earnings Report can be accessed here.

Posted on: 2017-08-24T13:29:00+05:00